In addition, ErbB3 has been shown to constitutively activate the PI3K pathway in prostate cancer cell lines (Lin et al, 1999; Jung et al, 2006), which may also lead to the constant NF-κB activation in prostate cancer cells. This evidence concerns the gene NFKB1 and prostate carcinoma.